BIOMAT Database Logo BIOMAT Database Logo

[Effect of pulse therapy using 1 alpha(OH)D on secondary hyperparathyroidism in patients on maintenance hemodialysis]. 1990

K Yoshida, and A Hirayama, and N Tanaka, and M Yasukawa, and M Saka, and Y Kaneko, and Y Maruyama, and Y Motomiya, and S Ozono, and Y Hirao
Department of Urology, Nara Medical University.

The effect of pulse therapy on severe secondary hyperparathyroidism related to chronic renal failure has been examined in 11 patients on maintenance hemodialysis by using an oral administration of 8 micrograms of 1 alpha(OH)D maximum per week. Throughout the 10 months of this treatment, the serum levels of intact-PTH, HS-PTH, and C-PTH were followed up. Additionally, to estimate the peak level of 1,25(OH)2D, its serum concentration at 10 hours after the 1 alpha (OH)D ingestion was measured. Results have shown that the serum levels of the intact-PTH, HS-PTH, and C-PTH were lowered in 9 of these 11 patients, two of this number especially showing a marked suppression of the serum intact-PTH to a low that was near to the normal upper limit level. In the two other cases of these 11 patients, no suppression was seen in any of serum PTH levels throughout the 10 months. In the cases that showed a good response, the 1,25(OH)2D serum concentration elevated significantly, to more than 100 pg/ml at 10 hours after the 1 alpha (OH)D intake. In contrast, in the 2 cases that showed no response, no appreciable elevation in the serum concentrations was noted. Thus, since the pulse therapy using 1 alpha (OH)D decreased the serum levels of the intact-PTH, HS-PTH, and C-PTH in 9 out of the 11 cases, we have concluded that pulse therapy using 1 alpha(OH)D is a valid therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis.

UI MeSH Term Description Entries
D006962 Hyperparathyroidism, Secondary Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY. Secondary Hyperparathyroidism,Hyperparathyroidisms, Secondary,Secondary Hyperparathyroidisms
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006887 Hydroxycholecalciferols Hydroxy analogs of vitamin D 3; (CHOLECALCIFEROL); including CALCIFEDIOL; CALCITRIOL; and 24,25-DIHYDROXYVITAMIN D 3. Hydroxyvitamins D,Hydroxycholecalciferol

Related Publications

K Yoshida, and A Hirayama, and N Tanaka, and M Yasukawa, and M Saka, and Y Kaneko, and Y Maruyama, and Y Motomiya, and S Ozono, and Y Hirao
Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
January 1989, Nephron,
K Yoshida, and A Hirayama, and N Tanaka, and M Yasukawa, and M Saka, and Y Kaneko, and Y Maruyama, and Y Motomiya, and S Ozono, and Y Hirao
Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy.
January 1996, Nephron,
K Yoshida, and A Hirayama, and N Tanaka, and M Yasukawa, and M Saka, and Y Kaneko, and Y Maruyama, and Y Motomiya, and S Ozono, and Y Hirao
Secondary hyperparathyroidism in patients on maintenance hemodialysis.
November 1982, The Tokai journal of experimental and clinical medicine,
K Yoshida, and A Hirayama, and N Tanaka, and M Yasukawa, and M Saka, and Y Kaneko, and Y Maruyama, and Y Motomiya, and S Ozono, and Y Hirao
[A clinical study on active vitamin D pulse therapy in hemodialysis patients with secondary hyperparathyroidism].
March 2000, Hinyokika kiyo. Acta urologica Japonica,
K Yoshida, and A Hirayama, and N Tanaka, and M Yasukawa, and M Saka, and Y Kaneko, and Y Maruyama, and Y Motomiya, and S Ozono, and Y Hirao
Treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis.
October 1989, Nihon Jinzo Gakkai shi,
K Yoshida, and A Hirayama, and N Tanaka, and M Yasukawa, and M Saka, and Y Kaneko, and Y Maruyama, and Y Motomiya, and S Ozono, and Y Hirao
Effect of Hybrid Blood Purification Treatment on Secondary Hyperparathyroidism for Maintenance Hemodialysis Patients.
January 2018, Blood purification,
K Yoshida, and A Hirayama, and N Tanaka, and M Yasukawa, and M Saka, and Y Kaneko, and Y Maruyama, and Y Motomiya, and S Ozono, and Y Hirao
Intravenous alfacalcidol once weekly pulse therapy for secondary hyperparathyroidism in hemodialysis patients.
January 2011, Renal failure,
K Yoshida, and A Hirayama, and N Tanaka, and M Yasukawa, and M Saka, and Y Kaneko, and Y Maruyama, and Y Motomiya, and S Ozono, and Y Hirao
[Vitamin D "pulse" therapy for secondary hyperparathyroidism due to long-term hemodialysis in patients with chronic kidney failure].
December 1991, Nihon rinsho. Japanese journal of clinical medicine,
K Yoshida, and A Hirayama, and N Tanaka, and M Yasukawa, and M Saka, and Y Kaneko, and Y Maruyama, and Y Motomiya, and S Ozono, and Y Hirao
[The oral 1-25 dihydroxyvitamin D3 pulse therapy in hemodialysis patients for the early treatment of secondary hyperparathyroidism].
July 1992, Nihon Jinzo Gakkai shi,
K Yoshida, and A Hirayama, and N Tanaka, and M Yasukawa, and M Saka, and Y Kaneko, and Y Maruyama, and Y Motomiya, and S Ozono, and Y Hirao
Oral 1,25(OH)2D3 pulse therapy for the treatment of secondary hyperparathyroidism.
April 1993, Nihon Jinzo Gakkai shi,
Copied contents to your clipboard!